STAAR SURGICAL CO — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that STAAR SURGICAL CO filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $239.44M | Mar 3, 2026 |
| FY2025 | Dec 27, 2024 | $313.90M | Mar 3, 2026 |
| FY2025 | Dec 29, 2023 | $322.42M | Mar 3, 2026 |
| FY2025 | Dec 30, 2022 | $239.44M | Mar 3, 2026 |
| FY2021 | Dec 31, 2021 | $59.00M | Feb 23, 2022 |
| FY2021 | Oct 1, 2021 | $58.35M | Feb 23, 2022 |
| FY2021 | Jul 2, 2021 | $62.37M | Feb 23, 2022 |
| FY2021 | Apr 2, 2021 | $50.75M | Feb 23, 2022 |
| FY2021 | Jan 1, 2021 | $46.00M | Feb 23, 2022 |
| FY2021 | Oct 2, 2020 | $47.08M | Feb 23, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Jan 1, 2021 | $22.05M | Feb 24, 2021 |
| FY2020 | Jan 3, 2020 | $20.86M | Feb 24, 2021 |
| FY2020 | Dec 28, 2018 | $22.87M | Feb 24, 2021 |
| FY2019 | Dec 29, 2017 | $22.29M | Feb 26, 2020 |
| FY2018 | Dec 30, 2016 | $23.32M | Feb 21, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 29, 2017 | $90.61M | Feb 28, 2018 |
| FY2017 | Dec 30, 2016 | $82.43M | Feb 28, 2018 |
| FY2017 | Jan 1, 2016 | $77.12M | Feb 28, 2018 |
| FY2016 | Jan 2, 2015 | $74.99M | Mar 2, 2017 |
| FY2015 | Jan 3, 2014 | $72.22M | Mar 11, 2016 |
| FY2014 | Dec 28, 2012 | $63.78M | Mar 13, 2015 |
| FY2013 | Dec 30, 2011 | $62.77M | Mar 12, 2014 |
| FY2011 | Dec 31, 2010 | $54.96M | Mar 8, 2012 |
| FY2011 | Jan 1, 2010 | $51.06M | Mar 8, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $182.42M | Mar 3, 2026 |
| FY2025 | Dec 27, 2024 | $239.58M | Mar 3, 2026 |
| FY2025 | Dec 29, 2023 | $252.65M | Mar 3, 2026 |
| FY2024 | Dec 30, 2022 | $223.38M | Feb 21, 2025 |
| FY2021 | Dec 31, 2021 | $44.99M | Feb 23, 2022 |
| FY2021 | Oct 1, 2021 | $45.30M | Feb 23, 2022 |
| FY2021 | Jul 2, 2021 | $49.20M | Feb 23, 2022 |
| FY2021 | Apr 2, 2021 | $39.14M | Feb 23, 2022 |
| FY2021 | Jan 1, 2021 | $34.30M | Feb 23, 2022 |
| FY2021 | Oct 2, 2020 | $34.87M | Feb 23, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | ($80.45M) | Mar 3, 2026 |
| FY2025 | Dec 27, 2024 | ($20.21M) | Mar 3, 2026 |
| FY2025 | Dec 29, 2023 | $21.35M | Mar 3, 2026 |
| FY2024 | Dec 30, 2022 | $39.67M | Feb 21, 2025 |
| FY2021 | Dec 31, 2021 | $4.92M | Feb 23, 2022 |
| FY2021 | Oct 1, 2021 | $6.02M | Feb 23, 2022 |
| FY2021 | Jul 2, 2021 | $8.57M | Feb 23, 2022 |
| FY2021 | Apr 2, 2021 | $4.99M | Feb 23, 2022 |
| FY2021 | Jan 1, 2021 | $3.33M | Feb 23, 2022 |
| FY2021 | Oct 2, 2020 | $3.89M | Feb 23, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | ($91.71M) | Mar 3, 2026 |
| FY2025 | Dec 27, 2024 | ($12.61M) | Mar 3, 2026 |
| FY2025 | Dec 29, 2023 | $28.10M | Mar 3, 2026 |
| FY2024 | Dec 30, 2022 | $43.80M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $33.34M | Feb 27, 2024 |
| FY2022 | Jan 1, 2021 | $6.77M | Feb 23, 2023 |
| FY2021 | Jan 3, 2020 | $11.85M | Feb 23, 2022 |
| FY2020 | Dec 28, 2018 | $6.60M | Feb 24, 2021 |
| FY2019 | Dec 29, 2017 | ($3.63M) | Feb 26, 2020 |
| FY2018 | Dec 30, 2016 | ($12.66M) | Feb 21, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $40.06M | Mar 3, 2026 |
| FY2025 | Dec 27, 2024 | $45.32M | Mar 3, 2026 |
| FY2025 | Dec 29, 2023 | $40.48M | Mar 3, 2026 |
| FY2024 | Dec 30, 2022 | $35.98M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $33.86M | Feb 27, 2024 |
| FY2022 | Jan 1, 2021 | $31.92M | Feb 23, 2023 |
| FY2021 | Jan 3, 2020 | $25.30M | Feb 23, 2022 |
| FY2020 | Dec 28, 2018 | $22.03M | Feb 24, 2021 |
| FY2019 | Dec 29, 2017 | $20.04M | Feb 26, 2020 |
| FY2018 | Dec 30, 2016 | $20.67M | Feb 21, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $274.13M | Mar 3, 2026 |
| FY2025 | Dec 27, 2024 | $252.19M | Mar 3, 2026 |
| FY2025 | Dec 29, 2023 | $224.55M | Mar 3, 2026 |
| FY2024 | Dec 30, 2022 | $179.58M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $145.30M | Feb 27, 2024 |
| FY2022 | Jan 1, 2021 | $111.59M | Feb 23, 2023 |
| FY2021 | Jan 3, 2020 | $100.10M | Feb 23, 2022 |
| FY2020 | Dec 28, 2018 | $84.92M | Feb 24, 2021 |
| FY2019 | Dec 29, 2017 | $67.91M | Feb 26, 2020 |
| FY2018 | Dec 30, 2016 | $71.02M | Feb 21, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | ($34.23M) | Mar 3, 2026 |
| FY2025 | Dec 27, 2024 | $15.73M | Mar 3, 2026 |
| FY2025 | Dec 29, 2023 | $14.59M | Mar 3, 2026 |
| FY2024 | Dec 30, 2022 | $35.72M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $43.96M | Feb 27, 2024 |
| FY2022 | Jan 1, 2021 | $20.95M | Feb 23, 2023 |
| FY2021 | Jan 3, 2020 | $25.80M | Feb 23, 2022 |
| FY2020 | Dec 28, 2018 | $12.77M | Feb 24, 2021 |
| FY2019 | Dec 29, 2017 | $2.85M | Feb 26, 2020 |
| FY2018 | Dec 30, 2016 | $1.05M | Feb 21, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $5.82M | Mar 3, 2026 |
| FY2025 | Dec 27, 2024 | $23.39M | Mar 3, 2026 |
| FY2025 | Dec 29, 2023 | $18.19M | Mar 3, 2026 |
| FY2024 | Dec 30, 2022 | $18.11M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $13.65M | Feb 27, 2024 |
| FY2022 | Jan 1, 2021 | $8.40M | Feb 23, 2023 |
| FY2021 | Jan 3, 2020 | $10.10M | Feb 23, 2022 |
| FY2020 | Dec 28, 2018 | $2.25M | Feb 24, 2021 |
| FY2019 | Dec 29, 2017 | $1.05M | Feb 26, 2020 |
| FY2018 | Dec 30, 2016 | $3.21M | Feb 21, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $451.68M | Mar 3, 2026 |
| FY2025 | Dec 27, 2024 | $509.52M | Mar 3, 2026 |
| FY2024 | Dec 29, 2023 | $488.69M | Feb 21, 2025 |
| FY2023 | Dec 30, 2022 | $418.82M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $345.78M | Feb 23, 2023 |
| FY2021 | Jan 1, 2021 | $257.42M | Feb 23, 2022 |
| FY2020 | Jan 3, 2020 | $207.52M | Feb 24, 2021 |
| FY2019 | Dec 28, 2018 | $167.34M | Feb 26, 2020 |
| FY2018 | Dec 29, 2017 | $67.93M | Feb 21, 2019 |
| FY2017 | Dec 30, 2016 | $65.48M | Feb 28, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $107.49M | Mar 3, 2026 |
| FY2025 | Dec 27, 2024 | $112.19M | Mar 3, 2026 |
| FY2024 | Dec 29, 2023 | $102.74M | Feb 21, 2025 |
| FY2023 | Dec 30, 2022 | $82.71M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $87.22M | Feb 23, 2023 |
| FY2021 | Jan 1, 2021 | $60.19M | Feb 23, 2022 |
| FY2020 | Jan 3, 2020 | $47.64M | Feb 24, 2021 |
| FY2019 | Dec 28, 2018 | $34.91M | Feb 26, 2020 |
| FY2018 | Dec 29, 2017 | $25.00M | Feb 21, 2019 |
| FY2017 | Dec 30, 2016 | $27.57M | Feb 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $344.18M | Mar 3, 2026 |
| FY2025 | Dec 27, 2024 | $397.34M | Mar 3, 2026 |
| FY2025 | Dec 29, 2023 | $385.95M | Mar 3, 2026 |
| FY2025 | Dec 30, 2022 | $336.11M | Mar 3, 2026 |
| FY2024 | Dec 31, 2021 | $261.57M | Feb 21, 2025 |
| FY2023 | Jan 1, 2021 | $197.22M | Feb 27, 2024 |
| FY2022 | Jan 3, 2020 | $159.88M | Feb 23, 2023 |
| FY2021 | Dec 28, 2018 | $132.43M | Feb 23, 2022 |
| FY2020 | Dec 29, 2017 | $42.94M | Feb 24, 2021 |
| FY2019 | Dec 30, 2016 | $37.91M | Feb 26, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $1.79M | Mar 3, 2026 |
| FY2025 | Dec 27, 2024 | $1.79M | Mar 3, 2026 |
| FY2024 | Dec 29, 2023 | $1.79M | Feb 21, 2025 |
| FY2023 | Dec 30, 2022 | $1.79M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $1.79M | Feb 23, 2023 |
| FY2021 | Jan 1, 2021 | $1.79M | Feb 23, 2022 |
| FY2020 | Jan 3, 2020 | $1.79M | Feb 24, 2021 |
| FY2019 | Dec 28, 2018 | $1.79M | Feb 26, 2020 |
| FY2018 | Dec 29, 2017 | $1.79M | Feb 21, 2019 |
| FY2017 | Dec 30, 2016 | $1.79M | Feb 28, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | ($148.02M) | Mar 3, 2026 |
| FY2025 | Dec 27, 2024 | ($67.58M) | Mar 3, 2026 |
| FY2024 | Dec 29, 2023 | ($47.37M) | Feb 21, 2025 |
| FY2023 | Dec 30, 2022 | ($68.72M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($111.39M) | Feb 23, 2023 |
| FY2021 | Jan 1, 2021 | ($135.89M) | Feb 23, 2022 |
| FY2020 | Jan 3, 2020 | ($141.80M) | Feb 24, 2021 |
| FY2019 | Dec 28, 2018 | ($156.28M) | Feb 26, 2020 |
| FY2018 | Dec 29, 2017 | ($161.25M) | Feb 21, 2019 |
| FY2017 | Dec 30, 2016 | ($159.11M) | Feb 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $153.15M | Mar 3, 2026 |
| FY2025 | Dec 27, 2024 | $144.16M | Mar 3, 2026 |
| FY2024 | Dec 29, 2023 | $183.04M | Feb 21, 2025 |
| FY2023 | Dec 30, 2022 | $86.48M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $199.71M | Feb 23, 2023 |
| FY2021 | Jan 1, 2021 | $152.45M | Feb 23, 2022 |
| FY2020 | Jan 3, 2020 | $119.97M | Feb 24, 2021 |
| FY2020 | Dec 28, 2018 | $103.88M | Feb 24, 2021 |
| FY2019 | Dec 29, 2017 | $18.52M | Feb 26, 2020 |
| FY2018 | Dec 30, 2016 | $14.00M | Feb 21, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | (1) | Mar 3, 2026 |
| FY2025 | Dec 27, 2024 | 0 | Mar 3, 2026 |
| FY2025 | Dec 29, 2023 | 0 | Mar 3, 2026 |
| FY2024 | Dec 30, 2022 | 0 | Feb 21, 2025 |
| FY2021 | Dec 31, 2021 | 0 | Feb 23, 2022 |
| FY2021 | Oct 1, 2021 | 0 | Feb 23, 2022 |
| FY2021 | Jul 2, 2021 | 0 | Feb 23, 2022 |
| FY2021 | Apr 2, 2021 | 0 | Feb 23, 2022 |
| FY2021 | Jan 1, 2021 | 0 | Feb 23, 2022 |
| FY2021 | Oct 2, 2020 | 0 | Feb 23, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | (1) | Mar 3, 2026 |
| FY2025 | Dec 27, 2024 | 0 | Mar 3, 2026 |
| FY2025 | Dec 29, 2023 | 0 | Mar 3, 2026 |
| FY2024 | Dec 30, 2022 | 0 | Feb 21, 2025 |
| FY2021 | Dec 31, 2021 | 0 | Feb 23, 2022 |
| FY2021 | Oct 1, 2021 | 0 | Feb 23, 2022 |
| FY2021 | Jul 2, 2021 | 0 | Feb 23, 2022 |
| FY2021 | Apr 2, 2021 | 0 | Feb 23, 2022 |
| FY2021 | Jan 1, 2021 | 0 | Feb 23, 2022 |
| FY2021 | Oct 2, 2020 | 0 | Feb 23, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | 49.40M | Mar 3, 2026 |
| FY2025 | Dec 27, 2024 | 49.29M | Mar 3, 2026 |
| FY2024 | Dec 29, 2023 | 48.84M | Feb 21, 2025 |
| FY2023 | Dec 30, 2022 | 48.21M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | 47.72M | Feb 23, 2023 |
| FY2021 | Jan 1, 2021 | 46.49M | Feb 23, 2022 |
| FY2020 | Jan 3, 2020 | 44.82M | Feb 24, 2021 |
| FY2019 | Dec 28, 2018 | 44.20M | Feb 26, 2020 |
| FY2018 | Dec 29, 2017 | 41.38M | Feb 21, 2019 |
| FY2017 | Dec 30, 2016 | 40,732 | Feb 28, 2018 |